David Cameron
Former UK prime minister David Cameron became a consultant for Illumina last month in order to help the company raise awareness about the benefits of genomics. Prior to his appointment, Cameron told the UK's Advisory Committee on Business Appointments that his main role would be to assist Illumina's engagement with foreign governments and stakeholders as it works and expands outside the UK, and that he would help with the formation of a new international advisory board and chair that board, which has not been established yet.
John Mattick
Genomics England has appointed John Mattick as its first CEO. Mattick will join Genomics England in June from Australia's Garvan Institute of Medical Research, which he has led since 2012. Mattick is noted for his scientific contributions to understanding the human genome, specifically his work showing that most of the genome is not evolutionary 'junk' but instead is devoted to an extensive RNA regulatory system that organizes human development. He will continue his academic career while in the UK at the University of Oxford's Green Templeton College, where he has been elected to a senior research fellowship for one day a week.
Paul Limburg
Exact Sciences has appointed Paul Limburg as co-chief medical officer. Limburg is a gastroenterologist and a professor of medicine at the Mayo Clinic, and serves as a co-leader of the Cancer Prevention and Control program within the Mayo Clinic Cancer Center. While at Mayo, he has also served as medical director of its global business solutions unit, and as medical director of several of its health and well-being programs. Limburg will advise Exact Sciences on research opportunities to inform, expand, and accelerate the adoption of effective colon cancer screening options such as Cologuard. He will continue to serve as a gastroenterologist with Mayo Clinic's Division of Gastroenterology and Hepatology, co-leader of the Cancer Prevention and Control program within Mayo Clinic Cancer Center, and principal investigator for the NCI-funded cancer prevention network clinical trials consortium.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.